Compare Novo Nordisk A/S (NVO) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Charles Schwab Corporation Common Stock — how do they compare? Novo Nordisk A/S trades at $45.02 (market cap $198.57B), while Charles Schwab Corporation Common Stock trades at $106.54 (market cap $184.24B). The key difference: Novo Nordisk A/S and Charles Schwab Corporation Common Stock are close in size by market cap, and Novo Nordisk A/S pays the higher dividend (4.03%). Which is the better fit depends on your goals.
| NVO | SCHW | |
|---|---|---|
Market Cap | $198.57B | $184.24B |
Sector | Health | Financials |
52-Week High | $63.98 | $113.65 |
52-Week Low | $35.29 | $85.35 |
Enterprise Value | $213.37B | — |
Dividend Yield | 4.03% | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
Charles Schwab (SCHW) trades at $106.87, down 2.21% with a bearish technical signal. The stock shows strong fundamentals with Q2 2026 EPS beating expectations at $1.62 vs. $1.56 expected, continuing a trend of earnings beats. Revenue grew to $23.92B in 2025 with a robust 38.79% net income margin. Analyst consensus is bullish with 57% buy ratings and a $122.14 price target, representing 14% upside potential.
SCHW presents a compelling investment case with strong earnings momentum and expanding digital asset offerings, though near-term technical weakness and competitive pressures in the RIA custody space warrant caution. The company's diversified revenue streams and improving cash flow trends support long-term growth prospects despite current market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
